

Q1 2020 Report was published May 28, 2020

Dignitana's Q1 Report was published May 28, 2020. The Q1 Report showed growth of 23 percent over the same period of 2019 as demand for DigniCap increases.

"Through these unprecedented times we are finding new ways to do business. Cancer doesn't stop for a pandemic, and neither do we." – CEO William Cronin in Q1 Report [View all financial reports here.](#)

Company updates and presentations

Dignitana has invited investors and media to four presentations in the second quarter:

- April 2 – COVID-19 Business Update
- May 5 – Redeye Medtech & Diagnostics Seminar
- May 28 – Q1 Interim Report Presentation
- June 8 – Aktiespararna Småbolagsdagarna

[All presentations are posted here.](#)

Dignitana Annual General Meeting on June 25, 2020

On May 25, Dignitana published the Notice for the Annual General Meeting on June 25, 2020 in Lund. The Company is closely monitoring the development of COVID-19 and will provide information closer to the AGM if additional precautionary measures are necessary. [View agenda, proposals, other documents and AGM COVID-19 precautions here.](#)

DigniCap Availability

The DigniCap Scalp Cooling System is now available in 38 countries and in 30 states in the United States. The total New locations since the last newsletter include:

- Advocate Infusion Center - Libertyville, Illinois
- American Oncology Partners – Bethesda, Maryland
- American Oncology Partners - Cary, North Carolina

New master contract with AON in U.S.

May 28 Dignitana announced a new master contract with American Oncology Network (AON), an alliance of community oncology practices operating in 12 states in the U.S. This agreement allows any of the 45 AON locations to easily provide DigniCap Scalp Cooling for their patients. [Read more here.](#)

COVID-19 Updates

Dignitana is monitoring the global developments of the pandemic and remains focused on providing DigniCap products and services to customers while recognizing that certain changes are necessary to conduct business in a responsible manner. [Read COVID-19 updates here.](#)

DigniCap Delta observational study introduced

In the June 8 presentation at Småbolagsdagarna CEO William Cronin addressed Dignitana's focus on patients and clinical success.

His presentation included a preview of an ongoing observational study illustrating the high level of effectiveness of DigniCap Delta with even the most challenging chemotherapy regimens, such as Taxol Carboplatin + Anthracyclines (AC-T) as shown here.




MARISSA


- AC-T
Taxol Carboplatin
+ Adriamycin
- 16 cycles





Clinically superior against the toughest regimens



Chemo
1
Dec 6, 2019



Chemo
16
April 21, 2020



Dignitana AB, Traktorgränden 3, SE-226 60 Lund Sweden

Per MAR guidelines, company announcements are posted at www.dignitana.se and distributed to Nasdaq First North Growth Market, Nordic News Agencies, EU Transparency, and financial websites [Subscribe here](mailto:investorrelations@dignitana.com) to receive this newsletter by email or email investorrelations@dignitana.com